Artiva Biotherapeutics, Inc. (ARTV)

NGM – Real Time Price. Currency in USD

10.63

+0.03 (0.28%)

At close: May 12, 2026, 4:00 PM EDT

10.72

+0.09 (0.88%)

Pre-market: May 13, 2026, 5:37 AM EDT

$Artiva Biotherapeutics: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA$

08.05.2026

Artiva Biotherapeutics: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA

Artiva Biotherapeutics (ARTV) is maintained as a "Buy," driven by FDA alignment for a single phase 3 trial of AlloNK plus rituximab in refractory RA. Company's AlloNK plus rituximab demonstrated strong ACR50 response rates in early studies, with phase 3 initiation targeted for 2H 2026 and data expected in 2H 2028. The company addresses a significant unmet need in 3rd-line RA, targeting 150K–200K U.S. patients unresponsive to prior biologics, with a $5 billion spend on this population.

08.05.2026

Artiva Biotherapeutics Stock Slides Despite Positive Trial Data

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) are down on Friday as the company announced initial clinical data regarding its AlloNK (AB-101) in combination with rituximab for autoimmune diseases and a $300 million private placement.

08.05.2026

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced the pricing of an underwritten offering of 23,871,526 shares of its common stock at a price of $11.52 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 2,170,138 shares of common stock at a purchase price of $11.5199 per share, which equals the offering price per share of the common stock less the $0.0001 exercise price per share of each pre-funded warrant. All the shares of common stock and pre-funded warrants in the offering are being sold by Artiva.

08.05.2026

Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Initial AlloNK® (AB-101) clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no patients relapsing or requiring new immunomodulatory agents AlloNK treatment regimen demonstrated a consistent pattern of deep B-cell depletion and tolerability results supportive of outpatient administration in community rheumatology settings U.S. Food and Drug Administration (FDA) alignment on a single Phase 3 registrational randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 refractory RA patients, with ACR50 at six months as the primary endpoint; trial initiation planned for H2 2026 Multiple oral and poster presentations at EULAR 2026, including a late-breaking oral presentation on AlloNK clinical efficacy in refractory RA, Sjögren disease (SjD) and systemic sclerosis (SSc) SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced financial results for the first quarter ended March 31, 2026, and highlighted recent progress. “Artiva has reached an important inflection point, with positive initial clinical data across multiple autoimmune diseases and FDA alignment on a single Phase 3 registrational trial design in refractory RA,” said Fred Aslan, M.D.

08.05.2026

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial

08.04.2026

Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that Artiva management will participate in a panel as well as a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 2:15 p.m. EDT. To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva's website.

10.03.2026

Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026

Videos

No Data

There is no data to display

Press releases

08.05.2026

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

08.05.2026

Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

08.05.2026

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial

08.04.2026

Artiva Biotherapeutics, Inc. (ARTV)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Artiva Biotherapeutics, Inc. (ARTV)

Artiva Biotherapeutics: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA

Artiva Biotherapeutics Stock Slides Despite Positive Trial Data

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Videos

No Data

Press releases

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Artiva Biotherapeutics: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA

Artiva Biotherapeutics Stock Slides Despite Positive Trial Data

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Videos

No Data

Press releases

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Search stocks

Artiva Biotherapeutics, Inc. (ARTV)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Artiva Biotherapeutics, Inc. (ARTV)

Artiva Biotherapeutics: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA

Artiva Biotherapeutics Stock Slides Despite Positive Trial Data

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Videos

No Data

Press releases

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Artiva Biotherapeutics: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA

Artiva Biotherapeutics Stock Slides Despite Positive Trial Data

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Videos

No Data

Press releases

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference